Thyrocare Technologies: NCLT Sanctions Amalgamation of Docon with API Holdings
NCLT has sanctioned the amalgamation of Docon Technologies with API Holdings. Docon's 51.02% stake (8,12,00,000 shares) in Thyrocare Technologies will vest with API. The promoter group's total shareholding remains 51.02%.
The amalgamation involves the transfer of a significant shareholding (51.02%) within the promoter group. While the aggregate promoter shareholding remains the same, the change in the direct entity holding these shares could have medium-term implications for corporate control and strategic decisions. The actual operational impact will depend on the integration process and future strategies of API Holdings.
The announcement details a regulatory sanction for an amalgamation, which is a procedural corporate action. While it involves a transfer of shares within the promoter group, it does not immediately present a positive or negative financial impact on Thyrocare Technologies itself, hence the neutral sentiment.
Thyrocare Technologies Limited has announced that the Hon'ble National Company Law Tribunal (NCLT), Mumbai Bench, has sanctioned the Scheme of Amalgamation of Docon Technologies Private Limited (Transferor Company) with API Holdings Limited (Transferee Company). The order was pronounced on August 31, 2026. The Scheme will become operative upon the "Effective Date," which is contingent upon the completion or waiver of all conditions precedent, including the filing of the certified copy of the NCLT Order with the Registrar of Companies (RoC) in Form No. INC-28.
Upon the Scheme becoming effective, Docon will be amalgamated with API. All assets, liabilities, undertakings, rights, and obligations of Docon will be transferred to and vested in API. Consequently, Docon's entire shareholding in Thyrocare Technologies Limited, comprising 8,12,00,000 equity shares (51.02% of the paid-up share capital), will be transmitted and vested with API. Docon is a wholly-owned subsidiary of API, and both are part of the Promoter Group.
Following the Effective Date, API will hold the 51.02% shareholding in Thyrocare Technologies Limited, previously held by Docon. The aggregate shareholding of the Promoter and Promoter Group will remain unchanged at 51.02%. The shareholding pattern indicates that Docon Technologies Private Limited will hold Nil shares post-implementation, while API Holdings Limited will hold 8,12,00,000 shares, representing 51.02% of the total paid-up capital. The public shareholders will continue to hold 48.98%.
A plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.